AI Earnings Predictions for Armata Pharmaceuticals Inc. (ARMP)

EX-99.1

2 armp-ex99d1.htm

EX-99.1

Exhibit 99.1

​

Armata Pharmaceuticals Announces Financial Results for the Third Quarter 2026 and Provides Corporate Update

​

LOS ANGELES, Calif., November 12, 2026 -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its third quarter ended September 30, 2026, and provided a corporate update.

​

“We continue to advance toward our most important near-term objective: initiating the Phase 3 superiority study of AP-SA02,” said Armata’s Dr. Deborah Birx, Chief Executive Officer. “We have progressed from planning to establishing the operational infrastructure needed to execute a large, pivotal clinical study. Our manufacturing capabilities are well established, critical clinical trial preparations are progressing, and we continue to work closely with the U.S. Food and Drug Administration (“FDA”) to finalize the study design. Together, these accomplishments reflect the considerable effort and investment we have made to prepare for this important next stage of development, while maintaining fiscal discipline.”

​

“We believe the FDA’s recent Breakthrough Therapy designation further underscores AP-SA02’s clinical potential. We also appreciate the continued financial support of the U.S. Department of War (“DoW”), which comes at an important time as we prepare for this next critical stage of clinical development. We believe AP-SA02 has the potential to make a meaningful difference in patient care and, more broadly, provide a foundation for expanding our bacteriophage technology into additional indications. We are excited about the opportunity ahead and remain firmly focused on successfully executing our Phase 3 program,” concluded Dr. Birx.

​

Third Quarter 2026 and Recent Developments:

​

Preparations for AP-SA02 Phase 3 Program

​

Armata continued to make significant progress in clinical, regulatory, manufacturing, and operational preparations for the planned pivotal Phase 3 superiority study of AP-SA02, the Company’s intravenously administered multi-phage product candidate for adjunct treatment of complicated Staphylococcus aureus bacteremia (“SAB”) caused by methicillin-sensitive S. aureus (“MSSA”) or methicillin-resistant S. aureus (“MRSA”).

​

●Continued discussions with the FDA to finalize the study design and submitted protocol revisions in response to FDA feedback.

●Submitted responses to all Clinical, Chemistry, Manufacturing, and Controls (“CMC”), and Regulatory comments in the FDA’s End-of-Phase 2 meeting written response.

●Completed four engineering runs of AP-SA02 at the Company’s in-house cGMP manufacturing facility in Los Angeles, California. Production of clinical trial material for the planned Phase 3 study is underway, with one cGMP production run and vialing of AP-SA02 drug product completed in the third quarter of 2026.

●Advanced the qualification and validation of quality control release assays.

●Completed validation of critical utilities.

●Executed contracts with clinical research organizations to support study management.

●Continued negotiating clinical trial agreements with an initial group of U.S. clinical trial sites.

​

​

Collectively, these activities advance the Company’s preparations to initiate its planned pivotal Phase 3 superiority study, which is designed to support a future Biologics License Application (BLA) for AP-SA02. The Phase 3 study is expected to initiate in the second half of 2026, with exact timing depending on when FDA concurs with the protocol.

​

Regulatory

​

●Received FDA Breakthrough Therapy designation for AP-SA02 for adjunct treatment of complicated bacteremia caused by MSSA or MRSA. The designation is intended to expedite the review of medicines that treat a serious or life-threatening condition and have shown preliminary clinical evidence indicating the potential for substantial improvement over available therapies. AP-SA02 now holds Breakthrough Therapy, Fast Track and Qualified Infectious Disease Product designations, providing strong regulatory validation.

●Obtained FDA agreement on an Initial Pediatric Study Plan (“Agreed iPSP”) for future pediatric evaluation of AP-SA02 as an adjunct treatment for complicated SAB, with pediatric studies deferred pending safety and efficacy data from the planned adult Phase 3 program. We believe this plan supports potential pediatric expansion while prioritizing patient safety and efficient clinical development.

​

Funding

​

●Received $3.7 million in additional non-dilutive funding from the DoWi, the first funds received specifically for AP-SA02 Phase 3 execution under a previously announced award. This brings cumulative non-dilutive DoW funding under the award to approximate

SEC.gov | Request Rate Threshold Exceeded

U.S. Securities and Exchange Commission

You’ve Exceeded the SEC’s Traffic Limit

Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.

Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.

The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.

For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.

For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.

Reference ID: 0.c706d217.1784384629.d6a5b136

More Information

Internet Security Policy

By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.

Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).

To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.

If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.

Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.

Note: We do not offer technical support for developing or debugging scripted downloading processes.

SEC.gov | Request Rate Threshold Exceeded

U.S. Securities and Exchange Commission

You’ve Exceeded the SEC’s Traffic Limit

Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.

Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.

The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.

For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.

For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.

Reference ID: 0.c706d217.1784384631.d6a5d2ab

More Information

Internet Security Policy

By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.

Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).

To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.

If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.

Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.

Note: We do not offer technical support for developing or debugging scripted downloading processes.

ARMATA PHARMACEUTICALS, INC._November 12, 2025 false000092111400009211142025-11-122025-11-12 ​ ​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 12, 2025

ARMATA PHARMACEUTICALS, INC.

(Exact name of Registrant as specified in its charter) ​

Washington 001-37544 91-1549568

(State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.)

​ ​ ​ ​

​ ​

5005 McConnell Avenue Los Angeles, California ​ 90066

(Address of principal executive offices) (Zip Code)

​ (310) 655-2928 (Registrant’s Telephone number) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below): ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ​ ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ​ ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ​ ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) ​ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Securities registered pursuant to Section 12(b) of the Act: ​ ​

​

​

​

​

Title of Each Class

Trading Symbol(s)

Name of Each Exchange on Which Registered

Common Stock ​

ARMP

​ NYSE American

​ ​ ​ ​ ​

​ Item 2.02Results of Operations and Financial Condition. ​ On November 12, 2025, the Company announced its financial results for the three and nine months ended September 30, 2025, in the press release furnished hereto as Exhibit 99.1. ​ The information in this Item 2.02 and the attached Exhibit 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 2.02 and the attached Exhibit 99.1 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended. ​ ​ ​ Item 9.01Financial Statements and Exhibits. ​ (d)Exhibits. ​ ​

​

​

Exhibit No.

Description

99.1 ​ Press Release, dated November 12, 2025.

104 ​ Cover Page Interactive Data File (embedded within Inline XBRL document).

​ ​ ​

​

SIGNATURES

​ Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ​ ​

​

​

Date: November 12, 2025 Armata Pharmaceuticals, Inc.

​ ​

​ By: /s/ David House

​ Name: David House

​ Title: Senior Vice President, Finance and Principal Financial Officer

​ ​ ​ ​ ​

ARMATA PHARMACEUTICALS, INC._August 11, 2025 false000092111400009211142025-08-112025-08-11 ​ ​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 11, 2025

ARMATA PHARMACEUTICALS, INC.

(Exact name of Registrant as specified in its charter) ​

Washington 001-37544 91-1549568

(State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.)

​ ​ ​ ​

​ ​

5005 McConnell Avenue Los Angeles, California ​ 90066

(Address of principal executive offices) (Zip Code)

​ (310) 655-2928 (Registrant’s Telephone number) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below): ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ​ ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ​ ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ​ ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) ​ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Securities registered pursuant to Section 12(b) of the Act: ​ ​

​

​

​

​

Title of Each Class

Trading Symbol(s)

Name of Each Exchange on Which Registered

Common Stock ​

ARMP

​ NYSE American

​ ​ ​ ​ ​

​

Item 1.01 Entry into a Material Definitive Agreement.

On August 12, 2025, Armata Pharmaceuticals, Inc. (the “Company”) announced in the press release furnished hereto as Exhibit 99.1 that, on August 11, 2025, it had entered into, as borrower, a credit and security agreement (the “August 2025 Credit Agreement”) with Innoviva Strategic Opportunities LLC (“Innoviva”), a wholly owned subsidiary of Innoviva, Inc., a principal shareholder of the Company. The August 2025 Credit Agreement provides for a secured term loan facility in an aggregate amount of $15 million (the “Loan”) at an interest rate of 14.0% per annum, and has a maturity date of January 11, 2029. Repayment of the Loan is guaranteed by the Company’s domestic subsidiaries, and the Loan is secured by substantially all of the assets of the Company and the subsidiary guarantors.

The August 2025 Credit Agreement contains customary affirmative and negative covenants and representations and warranties, including financial reporting obligations and certain limitations on indebtedness, liens, investments, distributions (including dividends), collateral, investments, mergers or acquisitions and fundamental corporate changes. The August 2025 Credit Agreement also includes customary events of default, including payment defaults, breaches of provisions under the loan documents, certain losses or impairment of collateral and related security interests, the occurrence of certain events that could reasonably be expected to have a “material adverse effect” as set forth in the August 2025 Credit Agreement, certain bankruptcy or insolvency events, and a material deviation from the Company’s operating budget.

The foregoing description of the August 2025 Credit Agreement is qualified in its entirety by the full text of such document, which is filed as Exhibit 10.1, respectively, and is incorporated herein by reference. ​ Item 2.02Results of Operations and Financial Condition. ​ On August 12, 2025, the Company announced its financial results for the three and six months ended June 30, 2025, in the press release furnished hereto as Exhibit 99.1. ​ The information in this Item 2.02 and the attached Exhibit 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 2.02 and the attached Exhibit 99.1 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended. ​

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

​ The disclosure set forth under Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference. ​ ​

Item 7.01 Regulation FD Disclosure.

​ On August 12, 2025, the Company issued a press releas

ARMATA PHARMACEUTICALS, INC._May 14, 2025 false000092111400009211142025-05-142025-05-14 ​ ​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 14, 2025

ARMATA PHARMACEUTICALS, INC.

(Exact name of Registrant as specified in its charter) ​

Washington 001-37544 91-1549568

(State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.)

​ ​ ​ ​

​ ​

5005 McConnell Avenue Los Angeles, California ​ 90066

(Address of principal executive offices) (Zip Code)

​ (310) 655-2928 (Registrant’s Telephone number) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below): ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ​ ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ​ ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ​ ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) ​ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Securities registered pursuant to Section 12(b) of the Act: ​ ​

​

​

​

​

Title of Each Class

Trading Symbol(s)

Name of Each Exchange on Which Registered

Common Stock ​

ARMP

​ NYSE American

​ ​ ​ ​ ​

Item 2.02Results of Operations and Financial Condition. ​ On May 14, 2025, Armata Pharmaceuticals, Inc. (the “Company”) announced its financial results for the three months ended March 31, 2025, in the press release furnished hereto as Exhibit 99.1. ​ The information in this Item 2.02 and the attached Exhibit 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 2.02 and the attached Exhibit 99.1 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended. ​ Item 9.01Financial Statements and Exhibits. ​ (d)Exhibits. ​ ​

​

​

Exhibit No.

Description

99.1 ​ Press Release, dated May 14, 2025.

104 ​ Cover Page Interactive Data File (embedded within Inline XBRL document).

​ ​ ​

​

SIGNATURES

​ Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ​ ​

​

​

Date: May 14, 2025 Armata Pharmaceuticals, Inc.

​ ​

​ By: /s/ David House

​ Name: David House

​ Title: Senior Vice President, Finance and Principal Financial Officer

​ ​ ​ ​ ​

ARMATA PHARMACEUTICALS, INC._March 20, 2025 false000092111400009211142025-03-202025-03-20 ​ ​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 20, 2025

ARMATA PHARMACEUTICALS, INC.

(Exact name of Registrant as specified in its charter) ​

Washington 001-37544 91-1549568

(State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.)

​ ​ ​ ​

​ ​

5005 McConnell Avenue Los Angeles, California ​ 90066

(Address of principal executive offices) (Zip Code)

​ (310) 655-2928 (Registrant’s Telephone number) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below): ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ​ ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ​ ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ​ ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) ​ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Securities registered pursuant to Section 12(b) of the Act: ​ ​

​

​

​

​

Title of Each Class

Trading Symbol(s)

Name of Each Exchange on Which Registered

Common Stock ​

ARMP

​ NYSE American

​ ​ ​ ​ ​

Item 2.02Results of Operations and Financial Condition. ​ On March 20, 2025, Armata Pharmaceuticals, Inc. (the “Company”) announced its financial results for the three months and full fiscal year ended December 31, 2024, in the press release furnished hereto as Exhibit 99.1. ​ The information in this Item 2.02 and the attached Exhibit 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 2.02 and the attached Exhibit 99.1 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended. ​ Item 9.01Financial Statements and Exhibits. ​ (d)Exhibits. ​ ​

​

​

Exhibit No.

Description

99.1 ​ Press Release, dated March 20, 2025.

104 ​ Cover Page Interactive Data File (embedded within Inline XBRL document).

​ ​ ​

​

SIGNATURES

​ Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ​ ​

​

​

Date: March 20, 2025 Armata Pharmaceuticals, Inc.

​ ​

​ By: /s/ David House

​ Name: David House

​ Title: Senior Vice President, Finance and Principal Financial Officer

​ ​ ​ ​ ​

false000092111400009211142024-11-132024-11-13 ​ ​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 13, 2024

ARMATA PHARMACEUTICALS, INC.

(Exact name of Registrant as specified in its charter) ​

Washington 001-37544 91-1549568

(State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.)

​ ​ ​ ​

​ ​

5005 McConnell Avenue Los Angeles, California ​ 90066

(Address of principal executive offices) (Zip Code)

​ (310) 655-2928 (Registrant’s Telephone number) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below): ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ​ ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ​ ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ​ ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) ​ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Securities registered pursuant to Section 12(b) of the Act: ​ ​

​

​

​

​

Title of Each Class

Trading Symbol(s)

Name of Each Exchange on Which Registered

Common Stock ​

ARMP

​ NYSE American

​ ​ ​ ​ ​

Item 2.02Results of Operations and Financial Condition. ​ On November 13, 2024, Armata Pharmaceuticals, Inc. (the “Company”) announced its financial results for the three and nine months ended September 30, 2024, in the press release furnished hereto as Exhibit 99.1. ​ The information in this Item 2.02 and the attached Exhibit 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 2.02 and the attached Exhibit 99.1 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended. ​ Item 9.01Financial Statements and Exhibits. ​ (d)Exhibits. ​ ​

​

​

Exhibit No.

Description

99.1 ​ Press Release, dated November 13, 2024.

104 ​ Cover Page Interactive Data File (embedded within Inline XBRL document).

​ ​ ​

​

SIGNATURES

​ Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ​ ​

​

​

Date: November 13, 2024 Armata Pharmaceuticals, Inc.

​ ​

​ By: /s/ David House

​ Name: David House

​ Title: Senior Vice President, Finance and Principal Financial Officer

​ ​ ​ ​ ​

false000092111400009211142024-08-132024-08-13 ​ ​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 13, 2024

ARMATA PHARMACEUTICALS, INC.

(Exact name of Registrant as specified in its charter) ​

Washington 001-37544 91-1549568

(State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.)

​ ​ ​ ​

​ ​

5005 McConnell Avenue Los Angeles, California ​ 90066

(Address of principal executive offices) (Zip Code)

​ (310) 655-2928 (Registrant’s Telephone number) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below): ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ​ ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ​ ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ​ ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) ​ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Securities registered pursuant to Section 12(b) of the Act: ​ ​

​

​

​

​

Title of Each Class

Trading Symbol(s)

Name of Each Exchange on Which Registered

Common Stock ​

ARMP

​ NYSE American

​ ​ ​ ​ ​

Item 2.02Results of Operations and Financial Condition. ​ On August 13, 2024, Armata Pharmaceuticals, Inc. (the “Company”) announced its financial results for the three and six months ended June 30, 2024, in the press release furnished hereto as Exhibit 99.1. ​ The information in this Item 2.02 and the attached Exhibit 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 2.02 and the attached Exhibit 99.1 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended. ​ Item 9.01Financial Statements and Exhibits. ​ (d)Exhibits. ​ ​

​

​

Exhibit No.

Description

99.1 ​ Press Release, dated August 13, 2024.

104 ​ Cover Page Interactive Data File (embedded within Inline XBRL document).

​ ​ ​

​

SIGNATURES

​ Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ​ ​

​

​

Date: August 13, 2024 Armata Pharmaceuticals, Inc.

​ ​

​ By: /s/ Richard Rychlik

​ Name: Richard Rychlik

​ Title: Vice President, Corporate Controller

​ ​ ​ ​ ​

false000092111400009211142024-05-072024-05-07 ​ ​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 7, 2024

ARMATA PHARMACEUTICALS, INC.

(Exact name of Registrant as specified in its charter) ​

Washington 001-37544 91-1549568

(State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.)

​ ​ ​ ​

​ ​

5005 McConnell Avenue Los Angeles, California ​ 90066

(Address of principal executive offices) (Zip Code)

​ (310) 655-2928 (Registrant’s Telephone number) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below): ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ​ ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ​ ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ​ ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) ​ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Securities registered pursuant to Section 12(b) of the Act: ​ ​

​

​

​

​

Title of Each Class

Trading Symbol(s)

Name of Each Exchange on Which Registered

Common Stock ​

ARMP

​ NYSE American

​ ​ ​ ​ ​

Item 2.02Results of Operations and Financial Condition. ​ On May 7, 2024, Armata Pharmaceuticals, Inc. (the “Company”) announced its financial results for the three months ended March 31, 2024, in the press release furnished hereto as Exhibit 99.1. ​ The information in this Item 2.02 and the attached Exhibit 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 2.02 and the attached Exhibit 99.1 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended. ​ Item 9.01Financial Statements and Exhibits. ​ (d)Exhibits. ​ ​

​

​

Exhibit No.

Description

99.1 ​ Press Release, dated May 7, 2024.

104 ​ Cover Page Interactive Data File (embedded within Inline XBRL document).

​ ​ ​

​

SIGNATURES

​ Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ​ ​

​

​

Date: May 7, 2024 Armata Pharmaceuticals, Inc.

​ ​

​ By: /s/ Richard Rychlik

​ Name: Richard Rychlik

​ Title: Vice President, Corporate Controller

​ ​ ​ ​ ​

false000092111400009211142024-03-212024-03-21 ​ ​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 21, 2024

ARMATA PHARMACEUTICALS, INC.

(Exact name of Registrant as specified in its charter) ​

Washington 001-37544 91-1549568

(State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.)

​ ​ ​ ​

​ ​

5005 McConnell Avenue Los Angeles, California ​ 90066

(Address of principal executive offices) (Zip Code)

​ (310) 655-2928 (Registrant’s Telephone number) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below): ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ​ ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ​ ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ​ ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) ​ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Securities registered pursuant to Section 12(b) of the Act: ​ ​

​

​

​

​

Title of Each Class

Trading Symbol(s)

Name of Each Exchange on Which Registered

Common Stock ​

ARMP

​ NYSE American

​ ​ ​ ​ ​

Item 2.02Results of Operations and Financial Condition. ​ On March 21, 2024, Armata Pharmaceuticals, Inc. (the “Company”) announced its financial results for the three months and full fiscal year ended December 31, 2023, in the press release furnished hereto as Exhibit 99.1. ​ The information in this Item 2.02 and the attached Exhibit 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 2.02 and the attached Exhibit 99.1 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended. ​ Item 9.01Financial Statements and Exhibits. ​ (d)Exhibits. ​ ​

​

​

Exhibit No.

Description

99.1 ​ Press Release, dated March 21, 2024.

104 ​ Cover Page Interactive Data File (embedded within Inline XBRL document).

​ ​ ​

​

SIGNATURES

​ Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ​ ​

​

​

Date: March 21, 2024 Armata Pharmaceuticals, Inc.

​ ​

​ By: /s/ Richard Rychlik

​ Name: Richard Rychlik

​ Title: Vice President, Corporate Controller

​ ​ ​ ​ ​

false000092111400009211142023-11-142023-11-14 ​ ​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 14, 2023

ARMATA PHARMACEUTICALS, INC.

(Exact name of Registrant as specified in its charter) ​

Washington 001-37544 91-1549568

(State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.)

​ ​ ​ ​

​ ​

5005 McConnell Avenue Los Angeles, California ​ 90066

(Address of principal executive offices) (Zip Code)

​ (310) 655-2928 (Registrant’s Telephone number) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below): ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ​ ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ​ ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ​ ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) ​ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Securities registered pursuant to Section 12(b) of the Act: ​ ​

​

​

​

​

Title of Each Class

Trading Symbol(s)

Name of Each Exchange on Which Registered

Common Stock ​

ARMP

​ NYSE American

​ ​ ​ ​ ​

Item 2.02Results of Operations and Financial Condition. ​ On November 14, 2023, Armata Pharmaceuticals, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2023, in the press release furnished hereto as Exhibit 99.1. ​ The information in this Item 2.02 and the attached Exhibit 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 2.02 and the attached Exhibit 99.1 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended. ​ Item 9.01Financial Statements and Exhibits. ​ (d)Exhibits. ​ ​

​

​

Exhibit No.

Description

99.1 ​ Press Release, dated November 14, 2023.

104 ​ Cover Page Interactive Data File (embedded within Inline XBRL document).

​ ​ ​

​

SIGNATURES

​ Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ​ ​

​

​

Date: November 14, 2023 Armata Pharmaceuticals, Inc.

​ ​

​ By: /s/ Richard Rychlik

​ Name: Richard Rychlik

​ Title: Corporate Controller

​ ​ ​ ​ ​

0000921114 false

0000921114

2023-08-14 2023-08-14

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): August 14, 2023

ARMATA PHARMACEUTICALS, INC.

(Exact name of Registrant as specified in its charter)

Washington

001-37544

91-1549568

(State or other jurisdiction

of incorporation or organization)

(Commission File Number)

(IRS Employer Identification No.)

4503 Glencoe Avenue

Marina del Rey, California

90292

(Address of principal executive offices)

(Zip Code)

(310) 655-2928

(Registrant’s Telephone number)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class

Trading Symbol(s)

Name of Each Exchange on Which Registered

Common Stock

ARMP

NYSE American

Item 2.02 Results of Operations and Financial Condition.

On August 14, 2023, Armata Pharmaceuticals, Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2023, in the press release furnished hereto as Exhibit 99.1.

The information in this Item 2.02 and the attached Exhibit 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 2.02 and the attached Exhibit 99.1 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit

No.

Description

99.1

Press Release, dated August 14, 2023.

104

Cover Page Interactive Data File (embedded within Inline XBRL document).

- 2 -

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 14, 2023 Armata Pharmaceuticals, Inc.

By: /s/ Julianne Averill

Name: Julianne Averill

Title: Chief Financial Officer

- 3 -

0000921114 false

0000921114

2023-06-27 2023-06-27

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): June 27, 2023

ARMATA PHARMACEUTICALS, INC.

(Exact name of Registrant as specified in its charter)

Washington

001-37544

91-1549568

(State or other jurisdiction

of incorporation or organization)

(Commission File Number)

(IRS Employer Identification No.)

4503 Glencoe Avenue

Marina del Rey, California

90292

(Address of principal executive offices)

(Zip Code)

(310) 655-2928

(Registrant’s Telephone number)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class

Trading Symbol(s)

Name of Each Exchange on Which Registered

Common Stock

ARMP

NYSE American

Item 2.02 Shareholder Director Nominations.

The information set forth under Item 8.01 regarding the deadline for submitting proposals for director nominations is incorporated herein by reference.

Item 8.01 Other Events.

Armata Pharmaceuticals, Inc. (“Armata”) has set August 29, 2023 as the date for its 2023 annual meeting of stockholders (the “Annual Meeting”). The Annual Meeting will be held at our principal executive offices at 4503 Glencoe Avenue, Marina del Ray, California 90292 at 8:30 a.m. local time. Armata’s stockholders of record at the close of business on July 10, 2023, will be entitled to notice of the Annual Meeting and to vote upon matters considered at the Annual Meeting.

Because the date of the Annual Meeting represents a change of more than 30 days from the anniversary of Armata’s 2022 annual meeting of stockholders, Armata has set new deadlines for (i) the receipt of stockholder proposals submitted pursuant to Rule 14a-8 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), for inclusion in Armata’s proxy materials for the Annual Meeting (“Rule 14a-8 Deadline”) and (ii) receipt of stockholder proposals and director nominations submitted pursuant to Article II, Section 2.6 of Armata’s Amended and Restated Bylaws for consideration at the Annual Meeting (“Advance Notice Bylaws Provision Deadline”). The Rule 14a-8 Deadline is 5:00 p.m. (Eastern Time) on Friday, July 7, 2023, which Armata has determined to be a reasonable period of time before it expects to begin to print and send its proxy materials. The Advance Notice Bylaws Provision Deadline is 5:00 p.m. (Eastern Time) on Friday, July 7, 2023. Stockholder proposals and director nominations should be submitted in writing and must be received by the Corporate Secretary at Armata’s principal executive offices at Armata Pharmaceuticals, Inc., 4503 Glencoe Avenue, Marina del Ray, California 90292, by the Rule 14a-8 Deadline or the Advance Notice Bylaws Provision Deadline, as applicable, in order to be considered timely.

Stockholder proposals submitted in accordance with Rule 14a-8 of the Exchange Act must also comply with the remaining requirements of Rule 14a-8 of the Exchange Act in order to be considered for inclusion in the proxy materials for the Annual Meeting.

Stockholder proposals and nominations submitted pursuant to Armata’s advance notice bylaw provisions must also comply with the advance notice provisions contained in Armata’s Amended and Restated Bylaws and may be omitted if not in compliance with applicable requirements. Stockholders are urged to read the complete text of such advance notice provisions.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit

No.

Description

104

Cover Page Interactive Data File (embedded within Inline XBRL document).

- 2 -

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report

0000921114 false

0000921114

2023-05-11 2023-05-11

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): May 11, 2023

ARMATA PHARMACEUTICALS, INC.

(Exact name of Registrant as specified in its charter)

Washington

001-37544

91-1549568

(State or other jurisdiction

of incorporation or organization)

(Commission File Number)

(IRS Employer Identification No.)

4503 Glencoe Avenue

Marina del Rey, California

90292

(Address of principal executive offices)

(Zip Code)

(310) 655-2928

(Registrant’s Telephone number)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class

Trading Symbol(s)

Name of Each Exchange on Which Registered

Common Stock

ARMP

NYSE American

Item 2.02 Results of Operations and Financial Condition.

On May 11, 2023, Armata Pharmaceuticals, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2023, in the press release furnished hereto as Exhibit 99.1.

The information in this Item 2.02 and the attached Exhibit 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 2.02 and the attached Exhibit 99.1 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit

No.

Description

99.1

Press Release, dated May 11, 2023.

104

Cover Page Interactive Data File (embedded within Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 12, 2023 Armata Pharmaceuticals, Inc.

By: /s/ Julianne Averill

Name: Julianne Averill

Title: Chief Financial Officer

false000092111400009211142023-03-162023-03-16 ​ ​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 16, 2023

ARMATA PHARMACEUTICALS, INC.

(Exact name of Registrant as specified in its charter) ​

Washington 001-37544 91-1549568

(State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.)

​ ​ ​ ​

​ ​

4503 Glencoe Avenue Marina del Rey, California ​ 90292

(Address of principal executive offices) (Zip Code)

​ (310) 655-2928 (Registrant’s Telephone number) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below): ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ​ ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ​ ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ​ ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) ​ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Securities registered pursuant to Section 12(b) of the Act: ​ ​

​

​

​

​

Title of Each Class

Trading Symbol(s)

Name of Each Exchange on Which Registered

Common Stock ​

ARMP

​ NYSE American

​ ​ ​ ​ ​

Item 2.02Results of Operations and Financial Condition. ​ On March 16, 2023, Armata Pharmaceuticals, Inc. (the “Company”) announced its financial results for the three months and full fiscal year ended December 31, 2022, in the press release furnished hereto as Exhibit 99.1. ​ The information in this Item 2.02 and the attached Exhibit 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 2.02 and the attached Exhibit 99.1 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended. ​ Item 9.01Financial Statements and Exhibits. ​ (d)Exhibits. ​ ​

​

​

Exhibit No.

Description

99.1 ​ Press Release, dated March 16, 2023.

104 ​ Cover Page Interactive Data File (embedded within Inline XBRL document).

​ ​ ​

​

SIGNATURES

​ Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ​ Date: March 16, 2023 Armata Pharmaceuticals, Inc.

​ ​

​ By: /s/ Erin Butler

​ Name: Erin Butler

​ Title: Vice President, Finance & Administration

​ ​ ​ ​

0000921114 false

0000921114

2022-11-09 2022-11-09

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): Noveember 9, 2022

ARMATA PHARMACEUTICALS, INC.

(Exact name of Registrant as specified in its charter)

Washington 001-37544 91-1549568

(State or other jurisdiction of

incorporation or organization) (Commission File Number) (IRS Employer Identification No.)

4503 Glencoe Avenue

Marina del Rey, California

90292

(Address of principal executive offices) (Zip Code)

(310) 655-2928

(Registrant’s Telephone number)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class

Trading Symbol(s)

Name of Each Exchange on Which

Registered

Common Stock

ARMP

NYSE American

Item 2.02 Results of Operations and Financial Condition.

On November 9, 2022, Armata Pharmaceuticals, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2022, in the press release furnished hereto as Exhibit 99.1.

The information in this Item 2.02 and the attached Exhibit 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 2.02 and the attached Exhibit 99.1 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit

No.

Description

99.1

Press Release, dated November 9, 2022.

104

Cover Page Interactive Data File (embedded within Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 9, 2022 Armata Pharmaceuticals, Inc.

By: /s/ Erin Butler

Name: Erin Butler

Title: Vice President, Finance & Administration

0000921114 false

0000921114

2022-09-20 2022-09-20

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): September 20, 2022

ARMATA PHARMACEUTICALS, INC.

(Exact name of Registrant as specified in its charter)

Washington 001-37544 91-1549568

(State or other jurisdiction of

incorporation or organization) (Commission File Number) (IRS Employer Identification No.)

4503 Glencoe Avenue

Marina del Rey, California

90292

(Address of principal executive offices) (Zip Code)

(310) 655-2928

(Registrant’s Telephone number)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class

Trading Symbol(s)

Name of Each Exchange on Which

Registered

Common Stock

ARMP

NYSE American

Item 2.02 Shareholder Director Nominations.

The information set forth under Item 8.01 regarding the deadline for submitting proposals for director nominations is incorporated herein by reference.

Item 8.01 Other Events.

Armata Pharmaceuticals, Inc. (“Armata”) has set November 16, 2022 as the date for its 2022 annual meeting of stockholders (the “Annual Meeting”). The Annual Meeting will be held at our principal executive offices at 4503 Glencoe Avenue, Marina Del Ray, California 90292 at 8:30 a.m. local time. Armata’s stockholders of record at the close of business on October 11, 2022, will be entitled to notice of the Annual Meeting and to vote upon matters considered at the Annual Meeting.

Because the date of the Annual Meeting represents a change of more than 30 days from the anniversary of Armata’s 2021 annual meeting of stockholders, Armata has set new deadlines for (i) the receipt of stockholder proposals submitted pursuant to Rule 14a-8 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), for inclusion in Armata’s proxy materials for the Annual Meeting (“Rule 14a-8 Deadline”) and (ii) receipt of stockholder proposals and director nominations submitted pursuant to Article II, Section 2.6 of Armata’s Amended and Restated Bylaws for consideration at the Annual Meeting (“Advance Notice Bylaws Provision Deadline”). The Rule 14a-8 Deadline is 5:00 p.m. (Eastern Time) on Friday, September 30, 2022, which Armata has determined to be a reasonable period of time before it expects to begin to print and send its proxy materials. The Advance Notice Bylaws Provision Deadline is 5:00 p.m. (Eastern Time) on Friday, September 30, 2022. Stockholder proposals and director nominations should be submitted in writing and must be received by the Corporate Secretary at Armata’s principal executive offices at Armata Pharmaceuticals, Inc., 4503 Glencoe Avenue, Marina Del Ray, California 90292, by the Rule 14a-8 Deadline or the Advance Notice Bylaws Provision Deadline, as applicable, in order to be considered timely.

Stockholder proposals submitted in accordance with Rule 14a-8 of the Exchange Act must also comply with the remaining requirements of Rule 14a-8 of the Exchange Act in order to be considered for inclusion in the proxy materials for the Annual Meeting.

Stockholder proposals and nominations submitted pursuant to Armata’s advance notice bylaw provisions must also comply with the advance notice provisions contained in Armata’s Amended and Restated Bylaws and may be omitted if not in compliance with applicable requirements. Stockholders are urged to read the complete text of such advanced notice provisions.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.

Description

104

Cover Page Interactive Data File (embedded within Inline XBRL document).

- 2 -

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly ca

0000921114 false

0000921114

2022-08-11 2022-08-11

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): August 11, 2022

ARMATA PHARMACEUTICALS, INC.

(Exact name of Registrant as specified in its charter)

Washington 001-37544 91-1549568

(State or other jurisdiction of

incorporation or organization) (Commission File Number) (IRS Employer Identification No.)

4503 Glencoe Avenue

Marina del Rey, California

90292

(Address of principal executive offices) (Zip Code)

(310) 655-2928

(Registrant’s Telephone number)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class

Trading Symbol(s)

Name of Each Exchange on Which Registered

Common Stock

ARMP

NYSE American

Item 2.02 Results of Operations and Financial Condition.

On August 11, 2022, Armata Pharmaceuticals, Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2022, in the press release furnished hereto as Exhibit 99.1.

The information in this Item 2.02 and the attached Exhibit 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 2.02 and the attached Exhibit 99.1 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit

No.

Description

99.1

Press Release, dated August 11, 2022.

104

Cover Page Interactive Data File (embedded within Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 11, 2022 Armata Pharmaceuticals, Inc.

By: /s/ Erin Butler

Name: Erin Butler

Title: Vice President, Finance & Administration